Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
2021
Background:Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
34
References
2
Citations
NaN
KQI